PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27058300-0	2016	Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet"s signaling cascades as new outcome measures in clinical trials.	Lovastatin	0-10	mitogen-activated protein kinase 1	Mus musculus	20-23	
8940037-6	1996	Fractionation of the cell lysates on the FPLC Mono-Q column revealed that lovastatin inhibited insulin stimulation of ERK2 (and, to a lesser extent, ERK1) in 3T3-L1 fibroblasts and had no effect on the insulin-stimulated ERK2 in 3T3-L1 adipocytes.	Lovastatin	74-84	mitogen-activated protein kinase 1	Mus musculus	118-122	
8940037-6	1996	Fractionation of the cell lysates on the FPLC Mono-Q column revealed that lovastatin inhibited insulin stimulation of ERK2 (and, to a lesser extent, ERK1) in 3T3-L1 fibroblasts and had no effect on the insulin-stimulated ERK2 in 3T3-L1 adipocytes.	Lovastatin	74-84	mitogen-activated protein kinase 1	Mus musculus	221-225	
34107900-10	2021	The cholesterol inhibitor lovastatin diminished ERK/MAPK activation by A1542, thereby reducing leukemic cell death induced by this ERK1/2 agonist.	Lovastatin	26-36	mitogen-activated protein kinase 1	Mus musculus	48-51	
27058300-4	2016	Changes in ERK phosphorylation were correlated with clinical response to lovastatin.	Lovastatin	73-83	mitogen-activated protein kinase 1	Mus musculus	11-14	
25274808-9	2014	Treatment of En2(-/-) mice with lovastatin, an indirect inhibitor of ERK phosphorylation, markedly reduced ERK phosphorylation in the dentate gyrus, but was unable to rescue learning deficits in MWM-trained mutant mice.	Lovastatin	32-42	mitogen-activated protein kinase 1	Mus musculus	69-72	
25383899-4	2014	Furthermore, brief treatment with lovastatin reduces activation of the GTPase Ras-extracellular signal-related kinase (Erk) pathway in the brain and normalizes deficits in LTP and learning in adult Ptpn11(D61G/+) mice.	Lovastatin	34-44	mitogen-activated protein kinase 1	Mus musculus	119-122	
25274808-9	2014	Treatment of En2(-/-) mice with lovastatin, an indirect inhibitor of ERK phosphorylation, markedly reduced ERK phosphorylation in the dentate gyrus, but was unable to rescue learning deficits in MWM-trained mutant mice.	Lovastatin	32-42	mitogen-activated protein kinase 1	Mus musculus	107-110	
24846270-2	2014	Lovastatin has been shown to effectively induce apoptosis in mouse PHEO cells (MPC) and the more aggressive mouse tumor tissue-derived cells (MTT), which was accompanied by decreased phosphorylation of mitogen-activated kinase (MAPK) pathway players.	Lovastatin	0-10	mitogen-activated protein kinase 1	Mus musculus	228-232	
24846270-8	2014	Inhibition of MAPK1 and 3 phosphorylation following treatment with fluvastatin, simvastatin, and lovastatin was confirmed by western blot.	Lovastatin	97-107	mitogen-activated protein kinase 1	Mus musculus	14-19	
22715163-7	2012	Accordingly, we next examined the combination of NVP-BEZ235 with the established agent lovastatin, as this has been described to inhibit ERK signalling.	Lovastatin	87-97	mitogen-activated protein kinase 1	Mus musculus	137-140	
22715163-8	2012	Lovastatin alone significantly reduced MPC and MTT cell viability at therapeutically relevant doses and inhibited both ERK and AKT signalling, but increased mTORC1/p70S6K signalling.	Lovastatin	0-10	mitogen-activated protein kinase 1	Mus musculus	119-122	
22715163-9	2012	Combination treatment with NVP-BEZ235 and lovastatin showed a significant additive effect in MPC and MTT cells and resulted in inhibition of both AKT and mTORC1/p70S6K signalling without ERK up-regulation.	Lovastatin	42-52	mitogen-activated protein kinase 1	Mus musculus	187-190	
21757497-7	2011	Blockade of the RAS/ERK activation characteristic of Nf1(-/-) osteoprogenitors by lovastatin during embryonic development could attenuate the increased cortical porosity observed in mutant pups.	Lovastatin	82-92	mitogen-activated protein kinase 1	Mus musculus	20-23